Sugi Predict

Sugi Predict / Compounds / SCHEMBL708647

SCHEMBL708647

SCHEMBL708647

CCCCc1ccc(S(=O)(=O)NC(C)(C)C)s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ TSHR P16473 4/20 0.40
▸ HTT P42858 4/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ MMP2 P08253 2/20 0.37
▸ MMP9 P14780 2/20 0.37
▸ MMP1 P03956 1/20 0.37
▸ MMP3 P08254 1/20 0.37
▸ MMP8 P22894 1/20 0.37
▸ MMP14 P50281 1/20 0.37
▸ MMP25 Q9NPA2 1/20 0.37
▸ LMNA P02545 5/20 0.35
▸ RECQL P46063 1/20 0.35
▸ POLB P06746 2/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ MAPT P10636 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11459274 0.84 L3MBTL1 (0.51) SMN1; SMN2KMT2ATSHRHTTMEN1
SCHEMBL710939 0.77 L3MBTL1 (0.36) SMN1; SMN2KMT2ATSHRMEN1L3MBTL1
SCHEMBL21962759 0.77 KMT2A (0.38) SMN1; SMN2KMT2ATSHRHTTMEN1
SCHEMBL6613091 0.76 MEN1 (0.39) SMN1; SMN2KMT2ATSHRHTTMEN1
SCHEMBL6672357 0.76 SMN1; SMN2 (0.40) SMN1; SMN2KMT2ATSHRHTTMEN1
SCHEMBL11054324 0.72 KMT2A (0.43) SMN1; SMN2KMT2AHTTMEN1L3MBTL1
SCHEMBL6664916 0.72 ALDH1A1 (0.47) KMT2ATSHRHTTMEN1POLB
SCHEMBL10854100 0.71 MAPT (0.38) SMN1; SMN2KMT2AMEN1L3MBTL1LMNA
SCHEMBL8632622 0.71 CA2 (0.49) SMN1; SMN2LOX
SCHEMBL710923 0.71 AGTR2 (0.32) SMN1; SMN2KMT2ATSHRMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124638-B2 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2012-02-28 — — US disclosed
CN-1529697-B Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB 2010-09-22 — — CN disclosed
US-7652054-B2 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2010-01-26 — — US disclosed
US-20090326026-A1 Tricyclic Compounds Useful as Angiotensin II Agonists VICORE PHARMA AB 2009-12-31 — — US disclosed
EP-1395566-B1 TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS VICORE PHARMA AB (SE) 2007-09-12 — — EP disclosed
CN-1529697-A Tricyclic compounds useful as angiotensin II agonists ά�ƶ�ҩ�﹫˾ 2004-09-15 — — CN disclosed
US-20040167176-A1 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2004-08-26 — — US disclosed
US-5444067-A Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety MERCK & CO., INC. (US) 1995-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167176-A1 Tricyclic compounds useful as angiotensin II agonists AGTR1, AGTR2, NPY2R SMN1; SMN2 4394/4885KMT2A 2180/4885TSHR 398/4885
US-20090326026-A1 Tricyclic Compounds Useful as Angiotensin II Agonists AGTR2, AGTR1, NPY4R SMN1; SMN2 4272/4885KMT2A 2966/4885TSHR 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.